Simris Group (SIMRIS) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
12 Nov, 2025Executive summary
Net revenue for Q3 2025 fell 37% year-over-year to SEK 484k; for Jan–Sep 2025, revenue declined 31% to SEK 1,330k.
EBITDA for Q3 2025 was SEK -3,639k, down 22% year-over-year; for Jan–Sep 2025, EBITDA improved 28% to SEK -10,343k.
EBIT for Q3 2025 was SEK -7,152k, an 8% decline; for Jan–Sep 2025, EBIT improved 17% to SEK -21,133k.
Cash at period end was SEK 3,798k, up 93% year-over-year.
Leadership transition announced with Daniel Kubitza appointed interim CEO.
Financial highlights
Result before tax for Jan–Sep 2025 improved 20% to SEK -22,058k.
Cash flow from operating activities for Jan–Sep 2025 improved 29% to SEK -11,726k.
Equity at period end was SEK -14,259k, with solidity at -10.0%.
Earnings per share remained negative.
Outlook and guidance
Board warns current cash reserves may not cover operations through year-end; active efforts underway to secure additional funding.
Focus for next nine months is on advancing lead ADC compound Simris-121 through in-vivo studies and developing new payload classes.
Latest events from Simris Group
- Revenue declined sharply and liquidity is strained as the company pivots to biotech and seeks funding.SIMRIS
Q4 202528 Feb 2026 - EBITDA loss narrowed 51% in Q2, but liquidity remains a critical concern.SIMRIS
Q2 202513 Aug 2025 - Revenue up, losses narrowed, but urgent funding needed amid leadership and strategic shifts.SIMRIS
Q3 202413 Jun 2025 - EBITDA loss narrowed and new collaborations advanced Simris Group's ADC platform.SIMRIS
Q2 202413 Jun 2025 - Revenue plunged, losses narrowed, and urgent funding is needed for continued operations.SIMRIS
Q1 20256 Jun 2025 - Revenue fell, losses narrowed, and urgent funding is needed for continued operations.SIMRIS
Q4 20245 Jun 2025